RT Journal Article
T1 Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
A1 Nicoletti, Paola
A1 Devarbhavi, Harshad
A1 Goel, Ashish
A1 Venkatesan, Radha
A1 Eapen, Chundamannil E
A1 Grove, Jane I
A1 Zafer, Samreen
A1 Bjornsson, Einar
A1 Lucena, M Isabel
A1 Andrade, Raul J
A1 Pirmohamed, Munir
A1 Wadelius, Mia
A1 Larrey, Dominique
A1 Maitland-van der Zee, Anke-Hilse
A1 Ibanez, Luisa
A1 Watkins, Paul B
A1 Daly, Ann K
A1 Aithal, Guruprasad P
AB Drug-induced liver injury (DILI) is a complication of treatment with antituberculosis (TB) drugs, especially in isoniazid (INH)-containing regimens. To investigate genetic risk factors, we performed a genomewide association study (GWAS) involving anti-TB DILI cases (55 Indian and 70 European) and controls (1,199 Indian and 10,397 European). Most cases were treated with a standard anti-TB drug regimen; all received INH. We imputed single nucleotide polymorphism and HLA genotypes and performed trans-ethnic meta-analysis on GWAS and candidate gene genotypes. GWAS found one significant association (rs117491755) in Europeans only. For HLA, HLA-B*52:01 was significant (meta-analysis odds ratio (OR) 2.67, 95% confidence interval (CI) 1.63-4.37, P = 9.4 × 10-5 ). For N-acetyltransferase 2 (NAT2), NAT2*5 frequency was lower in cases (OR 0.69, 95% CI 0.57-0.83, P = 0.01). NAT2*6 and NAT2*7 were more common, with homozygotes for NAT2*6 and/or NAT2*7 enriched among cases (OR 1.89, 95% CI 0.84-4.22, P = 0.004). We conclude HLA genotype makes a small contribution to TB drug-related DILI and that the NAT2 contribution is complex, but consistent with previous reports when differences in the metabolic effect of NAT2*5 compared with those of NAT2*6 and NAT2*7 are considered.
YR 2020
FD 2020-12-05
LK http://hdl.handle.net/10668/16520
UL http://hdl.handle.net/10668/16520
LA en
DS RISalud
RD Apr 10, 2025